DGAP-News: MeVis Medical Solutions AG: MeVis publishes figures for the first half of fiscal 2018/2019
DGAP-News: MeVis Medical Solutions AG / Key word(s): Half Year Results
MeVis Medical Solutions AG: MeVis publishes figures for the first half of fiscal 2018/2019
23.05.2019 / 16:00
The issuer is solely responsible for the content of this announcement.
Stable revenues and costs
- Revenues at EUR 4.0 million approximately 2 % above previous year's level
- EBIT of EUR 3.6 million in the first half year (compared to EUR 3.1 million in the previous year)
- EBIT margin stable at 44 % (previous year 38 %)
- Profit after tax of EUR 4.4 million (compared to EUR 2.4 million in the previous year)
Bremen, May 23, 2019 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, announces the results for the second quarter and first half of fiscal year 2018/2019 (reporting period October 1, 2018 to March 31, 2019).
Revenues in the second quarter of fiscal year 2018/2019 amounted to EUR 4,033 k, about 2 % above the previous year's level (EUR 3,950 k). License business declined by 23 % in the second quarter to EUR 1,104k (prev. year: EUR 1,438 k), and the maintenance business remained relatively constant at EUR 1,721 k (prev. year: EUR 1,712 k). The service business increased from EUR 799 k in the previous year's period to EUR 1,208 k. Revenues in the first half-year thus amounted to EUR 8,244 k (prev. year: EUR 8,233 k) and were allocated to the segments Digital Mammography with EUR 4,622 k (prev. year: EUR 5,710 k), Development Services with EUR 1,991 k (prev. year: EUR 767 k) and Other Operating Activities with EUR 1,631 k (prev. year: EUR 1,756 k). With a share of 56 % (prev. year: 69 %), the Digital Mammography segment continued to be the main source of revenues.
EBIT (Earnings before financial result and taxes) amounted to EUR 3,647 k in the reporting period (prev. year: EUR 3,136 k). At 44 %, the EBIT margin improved compared with a previous year's value of 38 %.
The financial result improved significantly in the reporting period to EUR 711 k (prev. year: EUR -768 k). The change compared with the previous year is due to the development of the balance of income and expenses from exchange rate differences of EUR 820 k (prev. year: EUR -1,280 k) and the deterioration in the result of the 51 % share in MeVis BreastCare GmbH & Co. KG of EUR -184 k (prev. year: EUR 444 k), which is recognized at equity.
Net profit after taxes therefore amounted to EUR 4,358 k (prev. year: EUR 2,366 k), corresponding with undiluted earnings per share of EUR 2.39 (prev. year: EUR 1.30).
The interim report for the third quarter of fiscal year 2018/2019 will be published on August 29, 2019.
Contact:
Kirchhoff, Marcus / CEO
23.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
MeVis Medical Solutions AG |
|
Caroline-Herschel-Str. 1 |
|
28359 Bremen |
|
Germany |
Phone: |
+49 421 224 95 0 |
Fax: |
+49 421 224 95 999 |
E-mail: |
[email protected] |
Internet: |
http://www.mevis.de |
ISIN: |
DE000A0LBFE4 |
WKN: |
A0LBFE |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
815311 |
|
End of News |
DGAP News Service |
815311 23.05.2019
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
18,54 |
16,76 |
18,07 |
17,13 |
16,21 |
18,76 |
17,34 |
EBITDA1,2 |
9,18 |
7,60 |
8,25 |
5,97 |
4,77 |
7,99 |
3,99 |
EBITDA-Marge3 |
49,51 |
45,35 |
45,66 |
34,85 |
29,43 |
42,59 |
|
EBIT1,4 |
7,96 |
6,69 |
8,00 |
5,81 |
4,64 |
7,90 |
3,89 |
EBIT-Marge5 |
42,93 |
39,92 |
44,27 |
33,92 |
28,62 |
42,11 |
22,43 |
Jahresüberschuss1 |
5,62 |
7,17 |
8,07 |
5,70 |
4,55 |
7,79 |
4,92 |
Netto-Marge6 |
30,31 |
42,78 |
44,66 |
33,27 |
28,07 |
41,52 |
28,37 |
Cashflow1,7 |
7,32 |
5,52 |
6,55 |
2,89 |
9,13 |
4,86 |
5,85 |
Ergebnis je Aktie8 |
3,09 |
3,94 |
4,43 |
3,13 |
2,50 |
4,28 |
2,70 |
Dividende8 |
0,95 |
0,95 |
0,95 |
0,95 |
0,95 |
0,95 |
0,95 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Deloitte
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
MeVis Med. Solutions |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A0LBFE |
25,200 |
Halten |
45,86 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
10,50 |
10,26 |
1,00 |
7,68 |
KBV |
KCV |
KUV |
EV/EBITDA |
2,57 |
7,83 |
2,64 |
10,70 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,95 |
0,95 |
3,77 |
19.03.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
- |
27.05.2025 |
- |
30.01.2025 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
5,34% |
0,58% |
0,00% |
-5,26% |
|
|